证券代码：003020 证券简称：立方制药 公告编号：2025-048 合肥立方制药股份有限公司 关于 2022 年限制性股票激励计划部分限制性股票回购注销完成 的公告 （一）2022 年 8 月 25 日，公司第四届董事会第二十一次会议审议通过了《关 于公司〈2022 年限制性股票激励计划（草案）〉及其摘要的议案》《关于公司 〈2022 年限制性股票激励计划实施考核管理办法〉的议案》《关于提请股东大会 授权董事会办理公司 2022 年限制性股票激励计划有关事宜的议案》，公司第四 届监事会第十五次会议审议通过了相关议案。公司独立董事就本期激励计划是否 有利于公司的持续发展及是否存在损害公司及全体股东利益的情形发表了独立 意见。 1 （二）2022 年 8 月 27 日至 2022 年 9 月 5 日，公司对本期激励计划首次授予 激励对象姓名和职务在公司内部 OA 系统进行了公示，截至公示期满，公司监事 会未收到任何异议。2022 年 9 月 7 日，公司监事会发布了《公司监事会关于 2022 年限制性股票激励计划首次授予部分激励对象名单的核查意见及公示情况说明》。 （三）2022 年 9 月 13 日，公司 ...

证券代码：003020 证券简称：立方制药 公告编号：2025-047 合肥立方制药股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、基本情况 合肥立方制药股份有限公司（以下简称"公司"或"立方制药"）于 2025 年 4 月 18 日召开第五届董事会第二十次会议，并于 2025 年 5 月 12 日召开 2024 年年度股东大会，审议通过了《关于变更公司注册资本并修订〈公司章程〉的议 案》，具体内容详见公司 2025 年 4 月 22 日在《证券时报》及巨潮资讯网 （www.cninfo.com.cn）披露的《关于变更公司注册资本并修订〈公司章程〉的公 告》（公告编号：2025-026）。 二、工商变更情况 公司已于近日完成上述注册资本变更的工商变更登记及备案手续，并取得了 合肥市市场监督管理局换发的《营业执照》，相关登记信息如下： 统一社会信用代码：91340100740870052B 名称：合肥立方制药股份有限公司 类型：股份有限公司（上市、自然人投资或控股） 住所：安徽省合肥市长江西路 669 ...

Core Viewpoint - On July 21, a total of 23 listed companies had their restricted shares unlocked, with a total market value of approximately 5.36 billion yuan [1] Summary by Category Restricted Share Unlocking - The specific details of the restricted share unlocking include: - Shandong High Energy (000803): 1.2772 million shares from equity incentive - Yueyang Xingchang (000819): 2.1525 million shares from equity incentive - Zhangyu A (000869): 2.0357 million shares from equity incentive - Sheneng Co., Ltd. (600642): 9.7161 million shares from equity incentive - Batian Co., Ltd. (002170): 1.2 million shares from equity incentive - Wanma Co., Ltd. (002276): 2.6112 million shares from equity incentive - Chuanfa Longmang (002312): 12.5 million shares from A-share issuance - Chengda Pharmaceutical (301201): 6.15594 million shares with extended lock-up period - Maoshuo Power (002660): 8.22983 million shares from A-share issuance - Laobaixing (603883): 193.6 thousand shares from equity incentive - Zhenbaodao (603567): 726.9 thousand shares from equity incentive - Lifang Pharmaceutical (003020): 234 thousand shares from equity incentive - Triangle Defense (300775): 110.4 thousand shares from equity incentive - Yidao Information (001314): 46.26 thousand shares from equity incentive - Honghe Technology (603256): 252.65 thousand shares from equity incentive - Guomao Co., Ltd. (603915): 165.8 thousand shares from equity incentive - Arrow Home (001322): 135.28 thousand shares from equity incentive - Hongying Intelligent (001266): 18 thousand shares from equity incentive - Kangpeng Technology (688602): 4.6189 million shares - Juyi Technology (688162): 108.1 thousand shares - Xidiwei (688173): 15.4 million shares - Aike Optoelectronics (688610): 68 thousand shares - Hangcai Co., Ltd. (688563): 180 thousand shares [1]

合肥立方制药股份有限公司（以下简称"公司"或"立方制药"）于近日接 到持股5%以上股东邓晓娟女士的通知，获悉其所持有本公司的部分股份解除了 质押，具体事项如下： | 股东 名称 | 是否为控股股 东或第一大股 东及其一致行 | 本次解除 质押股份 数量 | 占其所 持股份 | 占公司 总股本 | 起始日 | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 动人 | （股） | 比例 | 比例 | | | | | 邓晓娟 | 否 | 1,000,000 | 7.47% | 0.52% | 2024/6/18 | 2025/7/3 | 兴业银行股 份有限公司 | | | | | | | | | 合肥分行 | | 合计 | - | 1,000,000 | 7.47% | 0.52% | - | - | - | 证券代码：003020 证券简称：立方制药 公告编号：2025-046 合肥立方制药股份有限公司 关于持股 5%以上股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性 ...

Group 1 - The core point of the article is that Hefei Lifan Pharmaceutical has received approval for the production of Danpi Phenol, which enhances its raw material supply capacity and competitiveness in the market [1] - The new production process for Danpi Phenol is environmentally friendly and cost-effective, allowing for capacity expansion while meeting market demand [1] - The approval of Danpi Phenol is part of a series of product approvals this year, including the approval for the raw material of Docusate Sodium, which further enriches the company's product pipeline [1] Group 2 - The company has also received a clinical trial approval for Beipiduo Acid Tablets, marking a significant step in the development of lipid-lowering drugs and establishing a foundation for expansion in the cardiovascular treatment market [2] - Beipiduo Acid Tablets were originally approved in the U.S. in 2020, and Lifan Pharmaceutical is the third company in China to receive clinical approval, providing it with a first-mover advantage in this field [2] - The biopharmaceutical industry is projected to grow significantly, with the market size expected to reach 2.24 trillion yuan by 2025, indicating a competitive landscape where companies with core technologies and innovation capabilities are likely to succeed [2]

Group 1 - Taotao Automotive expects a net profit of 310 million to 360 million yuan for the first half of 2025, representing a year-on-year increase of 70.34% to 97.81% [1] - The company specializes in the research, production, and sales of all-terrain vehicles, electric golf carts, electric scooters, electric balance bikes, electric bicycles, and their accessories [1] - China Communications Construction Company plans to repurchase shares worth between 500 million to 1 billion yuan, with a maximum repurchase price of 13.58 yuan per share [1][2] Group 2 - Annoqi's subsidiary received a government subsidy of 1.65 million yuan, accounting for 34.77% of the company's latest audited net profit [2] - Annoqi focuses on the research, production, and sales of mid-to-high-end differentiated dyes [3] - Minfeng Special Paper announced the complete shutdown of its Nanhu plant, as its Haiyan plant is now capable of handling the production capacity [4] Group 3 - Aoto Electronics received a trademark registration certificate from Saudi Arabia, covering various electronic products [5] - Landi Group plans to acquire up to 20.1667% of the shares of Jujia Technology for a total price not exceeding 121 million yuan [6][7] - Lifan Pharmaceutical's Danpi phenol raw material drug has been approved for market launch, utilizing a new process that enhances efficiency and meets market demand [8] Group 4 - Shanghai Construction received a total of 548 million yuan in government subsidies, which accounts for 22.79% of the company's latest audited net profit [8] - Wanbangde's subsidiary received ethical approval for a key clinical trial of a new drug for Alzheimer's disease [8] - Prolo Pharmaceutical's subsidiary received approval for the market launch of a new raw material drug for liver cancer treatment [9] Group 5 - Chenguang New Materials received a government subsidy of 26 million yuan, representing 62.86% of the company's latest audited net profit [10] - Sanyou Medical's subsidiary received a government subsidy of 331,000 yuan, accounting for 28.86% of the company's latest audited net profit [11] - Weichai Heavy Machinery expects a net profit of 132 million to 151 million yuan for the first half of 2025, reflecting a year-on-year increase of 40% to 60% [12] Group 6 - Guanhao Biological announced the termination of its application for a specific stock issuance [13] - China Film plans to use up to 1.5 billion yuan of idle funds for cash management [14] - Aotai Biological intends to use up to 480 million yuan of idle raised funds for cash management [15] Group 7 - Helin Micro-Nano is planning to issue overseas shares and list on the Hong Kong Stock Exchange [17] - Jinpan Technology's vice president resigned due to personal health reasons [18] - Tongyi Zhong's chairman and general manager plan to reduce their shareholdings in the company [19] Group 8 - Naipu Mining signed an overseas contract worth 18.85 million USD [21] - Zhengye Technology completed an asset sale transaction worth 178 million yuan [23] - Lianxin Equipment won a bid for a project worth 157 million yuan from BOE [24] Group 9 - Smart Control plans to apply for a comprehensive credit line of up to 260 million yuan from banks [25] - Keyuan Pharmaceutical's application for issuing shares to purchase assets has been accepted by the Shenzhen Stock Exchange [27] - Meige Intelligent's H-share listing application materials have been received by the China Securities Regulatory Commission [29] Group 10 - Siwei Tuxin's subsidiary submitted an H-share listing application [32] - Metro Design's application for issuing shares to purchase assets has been accepted by the Shenzhen Stock Exchange [32] - Aeston submitted an application for H-share listing [34] Group 11 - Jiu Ri New Materials' shareholders plan to reduce their holdings by a total of 98,900 shares [34] - Yihua Tong's shareholder plans to reduce their holdings by up to 700,000 shares [35] - Xishanghai plans to distribute a cash dividend of 0.08 yuan per share [36] Group 12 - Zhejiang Natural plans to distribute a cash dividend of 1.97 yuan for every 10 shares [37] - Kouzi Jiao plans to distribute a cash dividend of 1.30 yuan per share [38] - Huitong Group plans to distribute a cash dividend of 0.023 yuan per share [40] Group 13 - Tongyong Co. plans to reduce its holdings by up to 0.31% of the company's shares [41] - China Shenhua plans to distribute a cash dividend of 2.26 yuan for every 10 shares [43] - Huangting International's executive director resigned due to personal reasons [45] Group 14 - Jinkai New Energy plans to distribute a cash dividend of 1 yuan for every 10 shares [46] - Heimu Dan plans to distribute a cash dividend of 0.041 yuan per share [47] - Feiyada plans to acquire all or part of the controlling stake in Chang Kong Gear [48]

证券代码：003020 证券简称：立方制药 公告编号：2025-045 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本 品符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执 行。 登记号：Y20240000104（受理号：CYHS2460182） 合肥立方制药股份有限公司 关于收到原料药上市申请批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，合肥立方制药股份有限公司（以下简称"公司"或"立方制药"） 收到国家药品监督管理局下发的丹皮酚《化学原料药上市申请批准通知书》。 现将相关情况公告如下： 一、《化学原料药上市申请批准通知书》主要内容 申请事项：境内生产化学原料药上市申请 化学原料药名称：丹皮酚 敬请广大投资者谨慎决策，注意投资风险。 特此公告。 合肥立方制药股份有限公司 董事会 通知书有效期：至2030年6月26日 二、丹皮酚的相关情况 丹皮酚作为中药单体成分，药理作用广泛，尤其对各种疼痛、肿瘤和心血 管疾病等疗效确切，其制剂丹皮酚软膏功能主治抗过敏，有消炎止痒作用，用 于各种湿疹，皮炎，皮肤瘙痒， ...

Group 1 - Hengbang Co., Ltd. plans to establish a joint venture with Huasheng Development with a registered capital of 10 million yuan, where Hengbang will contribute 8 million yuan (80%) and Huasheng will contribute 2 million yuan (20%) [1] - Hunan Gold's subsidiary Anhua Zhazi Creek Smelting Plant will undergo temporary maintenance starting from the end of June 2025, expected to last no more than 30 days [2] - Defu Technology's subsidiary signed supply agreements for lithium battery copper foil products with two leading global companies, with contract durations of 3 years and 5 years respectively [3] Group 2 - Binjiang Group won the rights to two residential land parcels for a total price of 4.368 billion yuan [5] - Zhong'an Technology announced the resignation of its executive vice president and board secretary due to personal reasons [7] - Changqing Technology's project for special polymer materials and electronic materials has officially commenced production, adding a capacity of 120,500 tons per year [10] Group 3 - Gansu Energy received approval from the China Securities Regulatory Commission to publicly issue bonds totaling up to 2 billion yuan [10] - Shuoshi Biology obtained a medical device registration certificate for an in vitro diagnostic reagent, valid until June 2030 [12] - Yawen Co., Ltd. plans to issue shares to specific investors, with the application accepted by the Shenzhen Stock Exchange [13] Group 4 - Guoyao Modern's subsidiary received approval for the listing of a raw material drug, which is a selective anticholinergic agent [16] - Inner Mongolia First Machinery's subsidiary signed a railway freight car procurement contract worth 130 million yuan [18] - Xining Special Steel plans to raise up to 1 billion yuan through a private placement to its controlling shareholder [39] Group 5 - Huadong Medicine's subsidiary received approval for a clinical trial of a new injectable drug targeting advanced solid tumors [29] - Warner Pharmaceutical's compound potassium hydrogen phosphate injection passed the consistency evaluation for generic drugs [30] - North Special Technology plans to raise up to 300 million yuan through a private placement for a production base project in Thailand [30] Group 6 - Xiangyang Technology is the first candidate for a 533 million yuan Airbus project [45] - Haishun New Materials intends to acquire 100% of Guangdong Zhengyi Packaging [46] - Jida Zhengyuan's shareholder plans to reduce their stake by up to 0.73% due to personal financial needs [47]

关于参股公司部分股权转让完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、交易概述 南京迈诺威医药科技有限公司（以下简称"迈诺威"）是合肥立方制药股份 有限公司（以下简称"公司"或"立方制药"）的参股公司，截至 2025 年 5 月 12 日，迈诺威注册资本为 525.6734 万元（人民币，下同），公司持有迈诺威 6.4984% 的股权。 公司于 2025 年 5 月 12 日召开第五届董事会第二十一次会议，审议通过了 《关于转让南京迈诺威医药科技有限公司部分股权的议案》，同意公司以 2,218.3748 万元的价格将持有的迈诺威 2.2184%的股权（对应注册资本 11.6614 万元）转让给成都元禾原点创业投资合伙企业（有限合伙）（以下简称"元禾创 投"）。同日，公司与元禾创投就本次股权转让事项签署了《股权转让协议》。 具体内容详见公司在《证券时报》和巨潮资讯网（http://www.cninfo.com.cn） 上披露的《关于转让参股公司部分股权的公告》（公告编号：2025-039）。 证券代码：003020 证券简称：立方制药 公告编号 ...

Core Viewpoint - The pharmaceutical sector, particularly innovative drug stocks, has gained significant attention in the capital market due to substantial transactions, policy benefits, and research outcomes, leading to a notable recovery in stock prices for many listed companies [1] Group 1: Market Performance - The Wind Innovative Drug Index (8841049) saw an increase of over 10% from May 15 to June 17, with total trading volume significantly rising during this period [1] - A total of 34 pharmaceutical companies announced share reduction plans, while 7 companies disclosed share buyback announcements during the same timeframe [2] Group 2: Share Reduction Plans - Key figures such as chairpersons and general managers from various companies, including Jiukang Biological and Kanglong Chemical, have announced plans to reduce their holdings, with reductions ranging from 0.93% to 4.8% of total shares [2] - The majority of these reductions are attributed to personal financial needs or debt repayment, with some aimed at optimizing shareholding structures [2] Group 3: Stock Price Movements - Certain companies, including Likang Pharmaceutical and Luoxin Pharmaceutical, experienced significant stock price increases of 28.71% to 30.28% during the same period, suggesting potential "high-level cashing out" scenarios [3] - Likang Pharmaceutical's stock surged following the approval of its product for ADHD treatment, indicating strong market interest due to limited competition [3] Group 4: Share Buyback and Increase Plans - Several companies, including Shanghai Laishi and Chengdu Xiandao, have announced share buyback or increase plans, reflecting confidence in their future value [6] - Shanghai Laishi's controlling shareholder plans to invest between 250 million to 500 million yuan in share purchases, emphasizing a commitment to stabilizing investor expectations [6][7] - Enhua Pharmaceutical's chairman also increased his holdings, demonstrating confidence in the company's growth prospects [8]